Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Application of Daptomycin in MRSA Infected Diabetic Foot in Comparison to Vancomycin Treatment.

Trial Profile

Application of Daptomycin in MRSA Infected Diabetic Foot in Comparison to Vancomycin Treatment.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 20 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daptomycin (Primary) ; Vancomycin
  • Indications Diabetic foot ulcer; Methicillin-resistant Staphylococcus aureus infections
  • Focus Therapeutic Use

Most Recent Events

  • 12 May 2012 New source identified and integrated (European Clinical Trials Databases; EudraCT2010-022348-18).
  • 26 Mar 2012 Actual patient number (1) added as reported by ClinicalTrials.gov.
  • 26 Mar 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top